Back to search results

Whole-body MRI and AI for Neurofibromatosis Type 1 in Children

This study is looking at a new way to find pre-cancerous growths in children with Neurofibromatosis Type 1 (NF1). Researchers are using special whole-body Magnetic Resonance Imaging (MRI) scans combined with Artificial Intelligence (AI) to do this. They want to see how reliable the MRI scans are and how well the AI can detect changes over time. You can join if you are between 5 and 17 years old and have a confirmed diagnosis of NF1. The study aims to enroll 15 children at Cedars-Sinai Medical Center. The main goal is to check if the MRI scans give consistent results and if the AI can accurately spot changes in the scans over a year.

Study design
This is a single-arm pilot study, meaning all 15 participants will receive the same intervention. It is not specified if it is blinded or open-label.
What's involved
You would have whole-body MRI scans at the beginning of the study, again at 1 month, and a final scan at 12 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months after the baseline scan, with the primary endpoint measured within 4 weeks of baseline.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04763109

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

Recruiting
NAAges 5–17Interventional
Nicole Baca
~15 participants
Updated 2026-05-07 on ClinicalTrials.gov
What's tested:Whole-body Magnetic Resonance Imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
For scan re-scan reliability, utilize T2 imaging to evaluate the agreement between the baseline scan and the 1 Month scan, which is performed within 4 weeks of the baseline scan.
Measured over From Baseline to within 4 weeks of baseline

Conditions

Neurofibromatosis Type 1

Explore related trials

Neurofibromatosis Type 1

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Nicole Baca, MD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center

Who to contact

Clinical Trial Recruitment Navigator
[email protected]
3104232133
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Between the ages of 5 and \<18 years at the start of study. If subject will turn 18 during the study, they will be allowed to enroll.
Clinically or molecularly confirmed diagnosis of NF-1. Subjects with mosaic/segmental NF-1 also qualify for the study.

Exclusion

Requiring sedation for imaging.
Implants and/or Devices: Mechanical, magnetic or electrical activated implants; Ferromagnetic implants and foreign bodies
Claustrophobia, problems being in enclosed spaces, or inability to lie facing upwards.
Allergy to animal dander or animal-instigated asthma.

What this trial measures

  • For scan re-scan reliability, utilize T2 imaging to evaluate the agreement between the baseline scan and the 1 Month scan, which is performed within 4 weeks of the baseline scan.From Baseline to within 4 weeks of baseline

    T2 is a type of high-resolution multiparametric tissue mapping that measures quantitative metrics of the physical properties of tissue and allows comparison in longitudinal follow-up